期刊文献+

诺舒阻抗控制子宫内膜切除系统治疗功能失调性子宫出血的疗效及安全性 被引量:4

Nosh impedance control endometrial ablation system for treatment of dysfunctional uterine bleeding efficacy and safety
下载PDF
导出
摘要 目的探究分析诺舒阻抗控制子宫内膜切除系统治疗功能失调性子宫出血的疗效及其安全性。方法选取本院收治的因功能性子宫出血患者86例进行研究,以随机数字表法分为对照组(n=40)和观察组(n=46),对照组实施宫腔镜下子宫内膜单极电切术,观察组采用诺舒阻抗控制子宫内膜切除系统治疗。对比两组治疗效果。结果观察组患者的手术时间、住院时间比对照组短,术中出血量均比对照组少,术后闭经发生率和并发症发生率比对照组低(P<0.05)。结论诺舒阻抗控制子宫内膜切除术在功能失调性子宫出血手术中运用,患者的闭经发生率和并发症发生率均比较低,临床治疗安全性比较高,具有较高的临床应用价值。 Objective To explore the efficacy and safety of Nosch impedance-controlled endometrial ablation system for treatment of dysfunctional uterine bleeding. Methods Eighty-six patients with functional uterine bleeding who were treated in our hospital were studied. They were randomly divided into control group(n=40) and observation group(n=46). The control group was performed hysteroscopic endometrium. Unipolar electrotomy was performed in the observation group using a Nosch impedance-controlled endometrial ablation system. Compare the treatment effects of the two groups. Results The operation time and length of stay in the observation group were shorter than those in the control group. The amount of intraoperative blood loss was less than that in the control group. The incidence of postoperative amenorrhea and the incidence of complications were lower than those in the control group(P〈0.05). Conclusion The use of Nosch impedance-controlled endometrial resection in the treatment of dysfunctional uterine bleeding has a low incidence of amenorrhea and complications. The safety of clinical treatment is relatively high, and it has high clinical application value.
作者 王琪 Wang Qi(Ganzhou People’s Hospital,Ganzhou,Jiangxi, 341000,China)
机构地区 赣州市人民医院
出处 《当代医学》 2018年第15期113-115,共3页 Contemporary Medicine
关键词 诺舒阻抗控制子宫内膜切除 功能失调性子宫出血 治疗效果 Nosch impedance control endometrial ablation Dysfunctional uterine bleeding Therapeutic effect
  • 相关文献

参考文献7

二级参考文献40

  • 1张福云,王文华,刘婷,曾华,胡萍,吴名桃.诺舒治疗无生育要求的异常子宫出血临床研究[J].医学信息,2017,30(4):55-56. 被引量:2
  • 2邵敬於,冯缵冲.实用宫腔镜学[M].上海:上海医科大学出版社,1999:120.
  • 3Davidson BR, Dipiero CM, Govoni KD, et al. Abnormal uterine bleeding during the reproductive years. J Midwifery Womens Health,2012, 57:248-254.
  • 4Pollock W, Jamieson W. Next-generation NovaSure device for endometrial ablation:assessing ease-of-use among physicians. Int J Womens Health ,2012,4 : 109-113.
  • 5Bongers MY. Second-generation endometrial ablation treatment: Novasure. Best Pract Res Clin Obstet Gynaecol, 2007, 21: 989- 994.
  • 6Kleijn JH, Engels R, Bourdrez P, et al. Five-year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. BJOG,2008,115 : 193-198.
  • 7Fakih M, Cherfan V, Abdallah E. Success rate, quality of life, and descriptive analysis after generalized endometrial ablation in an obese population. Int J Gynaecol Obstet,2011,113 : 120-123.
  • 8Asgari Z, Moini A, Samiee H, et al. Endometrial ablation with the NovaSure system in Iran. Int .1 Gvnaecol Obstet.2011 _ 114,73-75.
  • 9Davidson B R, Dipiero C M, Govoni K D, et al. Abnormal uterine bleeding during the reproductive years[J]. J Midwifery Womens Health,2012,57(3):248-254.
  • 10Pollock W, Jamieson W. Next-generation NovaSure device for endometrial ablation: assessing ease-of-use among physicians [J]. Int J Womens Health, 2012, 4(9): 109-113.

共引文献28

同被引文献59

引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部